Joining FORCEs Newsletter

Joining FORCES is the FORCE newsletter with news, views and supportive information for individuals concerned about hereditary breast and ovarian cancer.


Other BRCA Research at the University of Pennsylvania

by Sue Friedman

  • The PROSE study group is researching long-term outcomes in BRCA1/2 carriers who undergo early oophorectomy. Although effective at reducing breast and ovarian cancer risk, further information about long-term effects is needed, particularly regarding bone health and cardiovascular outcomes.
  • The University also participates in IMPACT, an international study evaluating prostate screening in men from families with BRCA1/2 mutations. Find more information and a list of participating sites at www.impact-study.co.uk/.
  • The Risk Modifier Study seeks to identify and characterize genes that affect cancer risk and clinical outcomes in people with BRCA1/2 mutations.

For more information on PROSE and other research at the University of Pennsylvania, contact their genetic counselor at 215-349-8141 or 215- 349-8143.

References

Domchek, SM et al., Association of Risk- Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. Journal of the American Medical Association (2010); 304:967-975.

Esserman, Laura and Kaklamani, V. Lessons Learned from Genetic Testing. Journal of the American Medical Association (2010); 304:1011-1012.

Feedback

We welcome your feedback. Please send your comments to Sue Friedman or fill out our Newsletter Feedback Form.

FORCE:Facing Our Risk of Cancer Empowered